205 related articles for article (PubMed ID: 30912195)
1. Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.
Feng Y; Lin J; Liu Y; Tang Y; Zhou Y; Zhong M
Int J Exp Pathol; 2019 Feb; 100(1):32-40. PubMed ID: 30912195
[TBL] [Abstract][Full Text] [Related]
2. The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.
Oon ML; Hoppe MM; Fan S; Phyu T; Phuong HM; Tan SY; Hue SS; Wang S; Poon LM; Chan HLE; Lee J; Chee YL; Chng WJ; de Mel S; Liu X; Jeyasekharan AD; Ng SB
Leuk Lymphoma; 2019 Dec; 60(13):3214-3224. PubMed ID: 31259656
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.
Han YB; Yang JM; Kwon HJ; Lee JO; Lee JS; Paik JH
Anticancer Res; 2021 Nov; 41(11):5677-5692. PubMed ID: 34732441
[TBL] [Abstract][Full Text] [Related]
5. C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas.
Huang W; Guo L; Liu H; Zheng B; Ying J; Lv N
Int J Clin Exp Pathol; 2014; 7(9):5634-44. PubMed ID: 25337204
[TBL] [Abstract][Full Text] [Related]
6. Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma.
Imai H; Sugimoto K; Isobe Y; Sasaki M; Yasuda H; Takeuchi K; Nakamura S; Kojima Y; Tomomatsu J; Oshimi K
Int J Hematol; 2009 Jun; 89(5):673-8. PubMed ID: 19452252
[TBL] [Abstract][Full Text] [Related]
7. High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(5):3498-503. PubMed ID: 22528513
[TBL] [Abstract][Full Text] [Related]
8. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
10. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
11. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
[TBL] [Abstract][Full Text] [Related]
12. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
[TBL] [Abstract][Full Text] [Related]
13. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
[TBL] [Abstract][Full Text] [Related]
14. Expression of PLK1 and survivin in diffuse large B-cell lymphoma.
Liu L; Zhang M; Zou P
Leuk Lymphoma; 2007 Nov; 48(11):2179-83. PubMed ID: 17943598
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD
J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
19. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
20. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
